



5151 CORPORATE WAY  
JUPITER, FL 33458-3101  
(866)720-8386

Client: <b>LA VITALITY</b>	20783	Patient: <b>NOACK, ADAM</b>	
9301 Wilshire Blvd		Phone: ( ) -	DOB: 10/04/1995 Age: 27 Sex: M
404		Address 1:	Fasting: N
BEVERLY HILLS, CA 90210		Address 2:	
Phys: KAWESCH, GARY	(561) 425-6354	City:	State: Zip: Page: 1

Acc# 004002194	Coll. Date: 06/09/23	Recv. Date: 06/12/23	Print Date: 06/13/23
Chart#	Coll. Time: 08:48 AM	Recv. Time: 10:58 AM	Print Time: 10:51
First reported on:	06/10/23 08:16	Final report date:	06/12/23

**Report Status: FINAL**

Test Name	Results	Reference Range	Units
*****OUT OF RANGE SUMMARY*****			
Glucose	101 H	70 - 99	mg/dL *I
reported: 06/10/23 08:13			
*****			
CBC With Differential/Platelet			
reported: 06/10/23 08:13			
WBC	5.9	3.4 - 10.8	x10E3/uL *I
RBC	5.34	4.14 - 5.80	x10E6/uL *I
Hemoglobin	16.1	13.0 - 17.7	g/dL *I
Hematocrit	46.9	37.5 - 51.0	% *I
MCV	88	79 - 97	fL *I
MCH	30.1	26.6 - 33.0	pg *I
MCHC	34.3	31.5 - 35.7	g/dL *I
RDW	11.8	11.6 - 15.4	% *I
Platelets	218	150 - 450	x10E3/uL *I
Neutrophils	64	Not Estab.	% *I
Lymphs	24	Not Estab.	% *I
Monocytes	9	Not Estab.	% *I
Eos	2	Not Estab.	% *I
Basos	1	Not Estab.	% *I
Neutrophils (Absolute)	3.8	1.4 - 7.0	x10E3/uL *I
Lymphs (Absolute)	1.4	0.7 - 3.1	x10E3/uL *I
Monocytes(Absolute)	0.5	0.1 - 0.9	x10E3/uL *I
Eos (Absolute)	0.1	0.0 - 0.4	x10E3/uL *I
Baso (Absolute)	0.0	0.0 - 0.2	x10E3/uL *I
Immature Granulocytes	0	Not Estab.	% *I
Immature Grans (Abs)	0.0	0.0 - 0.1	x10E3/uL *I
reported: 06/10/23 08:13			
Comp. Metabolic Panel (14)			
Glucose	101 H	70 - 99	mg/dL *I
BUN	19	6 - 20	mg/dL *I
Creatinine	0.98	0.76 - 1.27	mg/dL *I
eGFR	108	>59	mL/min/1.7 *I
BUN/Creatinine Ratio	19	9 - 20	*I
Sodium	140	134 - 144	mmol/L *I
Potassium	4.8	3.5 - 5.2	mmol/L *I

(Continued on Next Page)



5151 CORPORATE WAY  
JUPITER, FL 33458-3101  
(866)720-8386

Client: <b>LA VITALITY</b>	20783	Patient: <b>NOACK, ADAM</b>	
9301 Wilshire Blvd		Phone: ( ) -	DOB: 10/04/1995 Age: 27 Sex: M
404		Address 1:	Fasting: N
BEVERLY HILLS, CA 90210		Address 2:	
Phys: KAWESCH, GARY	(561) 425-6354	City:	State: Zip: Page: 2

Acc# 004002194	Coll. Date: 06/09/23	Recv. Date: 06/12/23	Print Date: 06/13/23
Chart#	Coll. Time: 08:48 AM	Recv. Time: 10:58 AM	Print Time: 10:51
First reported on:	06/10/23 08:16	Final report date:	06/12/23

**Report Status: FINAL**

Test Name	Results	Reference Range	Units
***** (Continued)			
Chloride	103	96 - 106	mmol/L *I
Carbon Dioxide, Total	25	20 - 29	mmol/L *I
Calcium	9.8	8.7 - 10.2	mg/dL *I
Protein, Total	7.4	6.0 - 8.5	g/dL *I
Albumin	5.1	4.1 - 5.2	g/dL *I
Globulin, Total	2.3	1.5 - 4.5	g/dL *I
A/G Ratio	2.2	1.2 - 2.2	*I
Bilirubin, Total	0.3	0.0 - 1.2	mg/dL *I
Alkaline Phosphatase	70	44 - 121	IU/L *I
AST (SGOT)	20	0 - 40	IU/L *I
ALT (SGPT)	25	0 - 44	IU/L *I

reported: 06/10/23 08:13

**Lipid Panel**

Cholesterol, Total	190	100 - 199	mg/dL *I
Triglycerides	60	0 - 149	mg/dL *I
HDL Cholesterol	83	>39	mg/dL *I
VLDL Cholesterol Cal	11	5 - 40	mg/dL *I
LDL Chol Calc (NIH)	96	0 - 99	mg/dL *I

reported: 06/10/23 08:13

Vitamin B12	583	232 - 1245	pg/mL *I
Prostate Specific Ag	0.4	0.0 - 4.0	ng/mL *I

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

reported: 06/10/23 08:13

TSH	1.030	0.450 - 4.500	uIU/mL *I
-----	-------	---------------	-----------

reported: 06/10/23 08:13

FSH	4.6	1.5 - 12.4	mIU/mL *I
-----	-----	------------	-----------

reported: 06/10/23 08:13

**Luteinizing Hormone(LH)**

(Continued on Next Page)

Client: <b>LA VITALITY</b>	20783	Patient: <b>NOACK, ADAM</b>	
9301 Wilshire Blvd		Phone: ( ) -	DOB: 10/04/1995 Age: 27 Sex: M
404		Address 1:	Fasting: N
BEVERLY HILLS, CA 90210		Address 2:	
Phys: KAWESCH, GARY	(561) 425-6354	City:	State: Zip: Page: 3

Acc# 004002194	Coll. Date: 06/09/23	Recv. Date: 06/12/23	Print Date: 06/13/23
Chart#	Coll. Time: 08:48 AM	Recv. Time: 10:58 AM	Print Time: 10:51
First reported on:	06/10/23 08:16	Final report date:	06/12/23

**Report Status: FINAL**

Test Name	Results	Reference Range	Units
<b>***** (Continued)</b>			
LH	4.8	1.7 - 8.6	mIU/mL *I
Estradiol	27.3	7.6 - 42.6	pg/mL *I
Roche ECLIA methodology			
reported: 06/10/23 08:13			
<b>Testosterone Free, Profile I</b>			
Testosterone	538	264 - 916	ng/dL *I
Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017;102;1161-1173. PMID: 28324103.			
Sex Horm Binding Glob, Serum	35.9	16.5 - 55.9	nmol/L *I
Testost., Free, Calc	99.0	47.7 - 173.9	pg/mL *I
reported: 06/10/23 08:13			
Hemoglobin A1c	5.3	4.8 - 5.6	% *I
Prediabetes: 5.7 - 6.4			
Diabetes: >6.4			
Glycemic control for adults with diabetes: <7.0			
reported: 06/12/23 19:06			
<b>IGF-1</b>			
Insulin-Like Growth Factor I	233	101 - 307	ng/mL *I
reported: 06/10/23 08:13			
Vitamin D, 25-Hydroxy	37.7	30.0 - 100.0	ng/mL *I
Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).			
1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.			
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.			

COMMENTS:

END OF REPORT

(Continued on Next Page)



5151 CORPORATE WAY  
JUPITER, FL 33458-3101  
(866)720-8386

Client: <b>LA VITALITY</b>	20783	Patient: <b>NOACK, ADAM</b>	
9301 Wilshire Blvd		Phone: ( ) -	DOB. 10/04/1995 Age:27 Sex:M
404		Address 1:	Fasting: N
BEVERLY HILLS, CA 90210		Address 2:	
Phys: KAWESCH, GARY	(561) 425-6354	City:	State: Zip: Page:4

Acc# 004002194	Coll. Date: 06/09/23	Recv. Date: 06/12/23	Print Date: 06/13/23
Chart#	Coll. Time: 08:48 AM	Recv. Time:10:58 AM	Print Time: 10:51
First reported on:	06/10/23 08:16	Final report date:	06/12/23

**Report Status: FINAL**

Test Name	Results	Reference Range	Units
-----------	---------	-----------------	-------

\*I) Unless otherwise noted, Tests Performed at :  
LABCORP, 5610 WEST LA SALLE STREET, TAMPA, FL 33607